The CAPS Medical solution overcomes the challenges of delivering NTAP to internal organs, selectively destroying cancer cells without damaging surrounding healthy tissue.
The company’s first area of focus in the $100B oncology therapeutics market: Non-muscle invasive bladder cancer (NMIBC). U.S. figures: 500k sufferers; 80k new patients annually.
CAPS plans to apply its solution to additional cancer types including lung, liver, breast, gastrointestinal, and others. CAPS Medical’s solution is on track to make a profound and needed impact.